Fridays Review: GLP-1 Compounding Standards

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Fridays Review is an independent assessment platform focused on evaluating compounded medication providers and their quality standards. As GLP-1 medications grow in popularity for weight management and metabolic health, consumers increasingly turn to third-party reviews to understand pharmacy credentials, ingredient sourcing, and clinical outcomes. A 2024 survey found 67% of patients researching compounded medications prioritize third-party verification before enrollment.

Fridays Review matters because the compounded GLP-1 market lacks unified regulatory oversight—unlike branded medications. Understanding what Fridays Review evaluates, how it differs from other platforms, and what clinical evidence supports compounded GLP-1 therapy can guide your conversation with healthcare providers. PlexusDx's approach emphasizes 503A-licensed pharmacy partnerships and optional genetic testing to support individualized treatment planning.

What Fridays Review Evaluates in Compounded GLP-1 Providers

Fridays Review assesses compounders across multiple dimensions: pharmacy licensing (state and federal), quality-control protocols, ingredient sourcing transparency, clinical safety reporting, and patient satisfaction metrics. Reviewers examine whether a compounder partners with accredited 503A facilities versus unlicensed 503B operations—a critical distinction in regulatory oversight and manufacturing standards.

The platform also rates patient communication practices, pricing transparency, and adverse event documentation. Fridays Review users report that providers with clear USP <797> compliance documentation and independent sterility testing tend to score higher. This transparency helps patients identify whether a given compounder operates under genuine pharmaceutical oversight or marketing-driven claims.

Fridays Review Score Criteria: A Clinical Comparison Framework

Fridays Review's scoring model combines regulatory compliance, clinical outcomes data, patient safety reports, and ingredient quality. Understanding these criteria helps you interpret reviews and compare providers. The framework below outlines the major evaluation dimensions.

Evaluation Dimension	What It Measures	Clinical Relevance	Typical Score Range
Pharmacy Licensing	State board registration, DEA compliance, 503A vs. 503B status	Ensures legal compounding authority and manufacturing oversight	Pass/Fail or 8–10/10
Quality Control	Sterility testing, potency assays, USP <797> adherence	Confirms active ingredient consistency and contamination prevention	7–10/10
Ingredient Sourcing	Pharmaceutical-grade APIs, third-party suppliers, lot traceability	Reduces impurity risk and supports reproducible dosing	6–10/10
Patient Safety Record	Adverse events reported, complaints resolved, transparency	Documents real-world tolerability and provider accountability	5–10/10

Fridays Review and Compounded Semaglutide vs. Tirzepatide: Clinical Context

Fridays Review distinguishes between single-agent (semaglutide) and dual-agent (tirzepatide) compounded formulations based on clinical evidence and manufacturing complexity. Compounded semaglutide targets GLP-1 receptors alone, while tirzepatide engages both GLP-1 and GIP receptors. Tirzepatide typically requires more rigorous quality controls due to dual-ingredient stability.

Providers rated highly on Fridays Review usually provide lab data supporting their tirzepatide stability claims and document storage conditions that preserve potency. PlexusDx offers both compounded semaglutide (starting $179/month) and tirzepatide (starting $229/month) through verified 503A pharmacies, with optional genetic testing to help identify which pathway may align better with individual metabolic profiles.

How Fridays Review Scores Differ from FDA Standards

Fridays Review operates independently of FDA approval processes. The FDA regulates branded GLP-1 drugs (Ozempic, Wegovy, Mounjaro) through rigorous efficacy and safety trials, but compounded medications fall under state pharmacy board jurisdiction and USP standards. Fridays Review fills this gap by assessing quality metrics not formally required by regulators.

This means a high Fridays Review score reflects good manufacturing practices and patient-reported safety—but not FDA-approved efficacy data. Compounded semaglutide and tirzepatide have clinical literature supporting their use, yet individual compounder formulations are not formally approved by the FDA. Fridays Review helps distinguish between compounder transparency and actual pharmaceutical rigor.

Genetic Insights and Personalized GLP-1 Selection

Beyond Fridays Review's pharmacy-level assessment, emerging evidence suggests genetic variation in GLP-1 and GIPR signaling pathways may influence individual response patterns. Variants in GLP1R (rs6923761), GIPR (rs1800437), and related genes show associations with appetite regulation and weight-loss trajectories in observational studies. PlexusDx's Precision Peptide Genetic Test ($99 add-on or $298 standalone) examines these pathway predispositions to support more informed provider conversations.

This genetic context does not predict exact medication response—response is multifactorial, involving dosing, adherence, diet, exercise, and comorbidities. However, understanding your genetic landscape in peptide pathways may help clinicians discuss whether single-agent (semaglutide) or dual-agent (tirzepatide) formulations, or adjusted dosing protocols, align with your underlying biology. PlexusDx interprets results with licensed healthcare providers.

Safety Considerations and Fridays Review Transparency

Fridays Review examines how providers document and respond to adverse events. Common GLP-1 side effects include nausea, vomiting, constipation, and pancreatitis risk (rare). Highly-rated Fridays Review compounder usually disclose these risks, provide patient education materials, and maintain clear escalation protocols for serious adverse events.

Before starting any compounded GLP-1 therapy, confirm your chosen provider appears in Fridays Review data, has documented safety protocols, and offers provider support lines. Ask your healthcare provider whether they have experience with the specific compounder you're considering. PlexusDx coordinates with licensed 503A pharmacies that maintain adverse event logs and participate in transparency initiatives.

How PlexusDx Supports a More Personalized Approach

PlexusDx's commitment to 503A-licensed compounding pharmacies means every semaglutide and tirzepatide formulation undergoes state pharmacy board oversight and USP <797> standards. While this does not replace FDA approval, it ensures manufacturing transparency and accountability. PlexusDx also maintains partnerships with providers who welcome third-party review platforms like Fridays Review—a sign of genuine quality confidence.

The Precision Peptide Genetic Test offers an additional layer of personalization. By examining genetic predispositions in peptide-signaling pathways (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313), PlexusDx helps you and your provider move beyond generic GLP-1 recommendations. Genetic insights may support discussions about whether compounded semaglutide, tirzepatide, or dual-compound formulas align with your metabolic architecture.

Your next step: Review your chosen compounder's Fridays Review profile, confirm 503A licensing, discuss genetic predispositions with your provider, and request a consultation with PlexusDx's team to explore which compounded formulation and starting protocol may fit your health goals and medical history.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What does Fridays Review specifically assess about compounded GLP-1 providers?

Fridays Review evaluates pharmacy licensing, quality-control protocols, ingredient sourcing, patient safety records, and pricing transparency. Providers with 503A licensing and USP <797> compliance typically score higher, reflecting genuine pharmaceutical oversight rather than marketing claims alone.

Is a high Fridays Review score the same as FDA approval?

No. Fridays Review assesses compounder quality and safety practices; the FDA approves branded medications through clinical trials. Compounded formulations follow state pharmacy rules and USP standards, which Fridays Review evaluates independently. A high score reflects transparency and rigor, not FDA approval.

How does PlexusDx compare to providers rated by Fridays Review?

PlexusDx partners exclusively with licensed 503A compounding pharmacies and supports Fridays Review–style transparency. PlexusDx also offers optional genetic testing (Precision Peptide, $99–$298) to help personalize semaglutide or tirzepatide selection alongside pharmacy quality assessment.

Should I prioritize Fridays Review ratings over my doctor's recommendation?

No. Fridays Review provides valuable compounder quality context; your healthcare provider should evaluate your medical eligibility, medication interactions, and contraindications. Use Fridays Review to verify pharmacy standards, then discuss results with your provider before enrollment.

Can genetic testing improve my GLP-1 outcomes if I choose a top Fridays Review provider?

Genetic predispositions in peptide pathways may inform personalized dosing or formulation choices when discussed with your provider—but do not guarantee outcomes. PlexusDx's Precision Peptide Test supports more informed conversations; combined with a high-quality compounder verified by Fridays Review, this dual approach maximizes transparency an...

Fridays Review: Compounded GLP-1 Quality and Clinical Pathways